Clinical trials: completed, sponsored by University College, London
Clear Cell Tumor, Gynecologic Cancer
A Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer
PEACOCC is a multi-centre, single arm, single stage phase II trial. The overall aim is to determine whether treatment with pembrolizumab is effective in patients with advanced clear cell gynaecological cancer.
- Conditions
- Clear Cell Tumor, Gynecologic Cancer, Advanced Cancer
- Trial name
- PEACOCC (NCT03425565)
- Testing
- Pembrolizumab
- Where
- 5 sites in United Kingdom
- Volunteers
- 48 people
- Sponsor
- University College, London
Ovarian Cancer, Fallopian Tube Cancer
Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer
The overall aim of the study is to demonstrate a clinically meaningful extension of progression free survival using maintenance pembrolizumab.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- PROMPT (NCT03430700)
- Testing
- Pembrolizumab
- Where
- 4 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- University College, London
Diffuse Large B Cell Lymphoma
Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy
The purpose of this trial is to compare the efficacy and safety of Inotuzumab Ozogamicin in combination with R-CVP with that of R-G-CVP for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) in a population of patients not…
- Trial name
- INCA (NCT01679119)
- Testing
- Cyclophosphamide, Vincristine, Prednisolone
- Where
- 40 sites in United Kingdom
- Volunteers
- 129 people
- Sponsor
- University College, London
Stroke, Aphasia
Digital Interventions in Neurorehabilitation: iTALKbetter
iTALKBetter will provide an app-based therapy for people with word retrieval difficulties who have had a stroke. This study aims to test the therapy application for people with naming difficulties through a small scale…
- Conditions
- Stroke, Aphasia, Anomia
- Trial name
- NCT04566081
- Testing
- iTalkBetter Trained Items, iTalkBetter Untrained Items
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- University College, London
Dementia, Alzheimer Disease
Digital Interventions in Neuro-Rehabilitation: Gotcha!
Aims and background Everyone forgets the names of people they should know at times. Having dementia makes this problem worse. People with dementia have told expressed they forget the names of people they care about and this can…
- Conditions
- Dementia, Alzheimer Disease, Anomia
- Trial name
- NCT04570215
- Testing
- Gotcha! Therapy application, Gotcha Therapy application: Maintenance
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- University College, London
COVID
Nebulised Rt-PA for ARDS Due to COVID-19
Some patients infected with COVID-19 develop a severe form of a lung disease called acute respiratory distress syndrome (ARDS). In these patients, the lungs become severely inflamed because of the virus.
- Trial name
- PACA (NCT04356833)
- Testing
- Nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 1, Nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 IMV, Nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 NIV
- Where
- United Kingdom
- Volunteers
- 35 people
- Sponsor
- University College, London
Secondary Progressive Multiple Sclerosis
Simvastatin in Secondary Progressive Multiple Sclerosis
Multiple sclerosis (MS) is a neurological condition which is a common cause of disability in young people. It is thought to be an autoimmune condition, where the body's immune system begins to attack itself.
- Trial name
- MS-OPT (NCT03896217)
- Testing
- Simvastatin
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- University College, London
Multiple System Atrophy
Exenatide Once-weekly as a Treatment for Multiple System Atrophy
Fifty patients with early stage Multiple System Atrophy (MSA) will be recruited and randomised to receive Exenatide injections, or to act as controls in this open label trial.
- Trial name
- MSA (NCT04431713)
- Testing
- Exenatide Pen Injector [Bydureon]
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University College, London
Siderosis, Neurological Disorder
Audiovestibular Function in Infratentorial Superficial Siderosis
One in six people in the United Kingdom and over 400 million people worldwide have disabling hearing loss. This figure will double by 2050 as predicted by the World Health Organisation.
- Conditions
- Siderosis, Neurological Disorder, Rare Diseases, Age Related Hearing Loss
- Trial name
- AViSS (NCT04200664)
- Testing
- Hearing assessment, Vestibular/balance assessment, Quality of life assessment
- Where
- 2 sites in United Kingdom
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University College, London
Polyps, Adenoma Colon
CADDIE Trial - Computer Aided Diagnosis and Detection for Intelligent Endoscopy
Background: Colonoscopy is accepted to be the gold standard for screening of colorectal cancer (CRC). Most CRCs develop from adenomatous polyps, with colonoscopy accepted to be the gold standard for screening of CRC.
- Conditions
- Polyps, Adenoma Colon, Colorectal Polyp, Colon Polyp
- Trial name
- CADDIE (NCT04325815)
- Testing
- CADDIE- Computer Aided (AI) Device used in Endoscopy
- Where
- United Kingdom
- Volunteers
- 739 people
- Sponsor
- University College, London
COVID-19 (Coronavirus Disease 2019), Hypoxia
Nebulised Dornase Alfa for Treatment of COVID-19 (Coronavirus Disease 2019)
An open-label, randomised, Best-Available-Care (BAC) and historic-controlled trial of nebulised dornase alfa [2.5 mg BID (bis in die)] for 7 days in participants with COVID-19 who are admitted to hospital and are at risk of…
- Trial name
- COVASE (NCT04359654)
- Testing
- Dornase Alfa Inhalation Solution [Pulmozyme]
- Where
- United Kingdom
- Volunteers
- 41 people
- Sponsor
- University College, London
Waldenstrom Macroglobulinemia
Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia
This study is for patients who have previously been treated for Waldenström's macroglobulinaemia (WM) and their disease has either not responded (known as refractory disease) or has returned (known as relapsed disease).
- Trial name
- PembroWM (NCT03630042)
- Testing
- Pembrolizumab, Rituximab
- Where
- 9 sites in United Kingdom
- Volunteers
- 17 people
- Sponsor
- University College, London
COVID19
Study of Plasma Exchange in Severe COVID-19
The rationale in severe COVID19 infection is to undertake PEX to aid reduction of the hyperinflammation and reduce the morbidity and mortality to the lungs, but also systemically, such as the heart, kidneys and brain.
- Trial name
- COVIPLEX (NCT04623255)
- Testing
- OCTAPLAS
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- University College, London
Muscle Tension Dysphonia, Vocal Fold Palsy
Evaluating the Feasibility of Acapella® Choice as a Dysphonia Treatment
A feasibility study to identify the immediate effect on the voices of patients with voice disorders (muscle tension dysphonia, vocal fold palsy or presbylaryngis) produced by exercising with Acapella Choice as a form of…
- Conditions
- Muscle Tension Dysphonia, Vocal Fold Palsy, Vocal Cord Paralysis, Presbylarynx
- Trial name
- NCT04764604
- Testing
- Acapella Choice, Tube-in-water
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- University College, London
Autism Spectrum Disorder
Efficacy of Vivomixx on Behaviour and Gut Function in Autism Spectrum Disorder
The purpose of this study is to assess the effects of 3 months supplementation with the multi strain probiotic Vivomixx on the overall function, aberrant behaviours and frequency of gastrointestinal symptoms in children with…
- Trial name
- VIVO-ASD (NCT03369431)
- Testing
- Vivomixx
- Where
- United Kingdom
- Volunteers
- 69 people
- Sponsor
- University College, London
Primary Alcohol Use Disorder
Ketamine for Reduction of Alcoholic Relapse
96 recently detoxified alcoholics will be randomized to receive either 3 sessions ketamine (0.8 mg/kg IV over 45 minutes) or placebo plus manualised psychological therapy, or 3 sessions of ketamine or placebo plus simple…
- Trial name
- KARE (NCT02649231)
- Testing
- Ketamine, Psychological Therapy, Alcohol Education
- Where
- 2 sites in United Kingdom
- Volunteers
- 96 people
- Sponsor
- University College, London
Amyloidosis
A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
This study evaluates the safety and efficacy of carfilzomib used in combination with thalidomide and dexamethasone in patients with relapsed AL amyloidosis.
- Trial name
- CATALYST (NCT02545907)
- Testing
- Carfilzomib, Thalidomide, Dexamethasone
- Where
- 14 sites in United Kingdom
- Volunteers
- 10 people
- Sponsor
- University College, London
Post Procedural Myocardial Infarction
Remote Ischaemic Postconditioning in the Clinical Setting of NSTEACS and Urgent PCI
This study investigates the cardioprotective effect of remote ischaemic pre-/postconditioning in patients presenting with a NSTEMI/Unstable angina undergoing PCI.
- Trial name
- NCT03726164
- Testing
- Remote Conditioning
- Volunteers
- 626 people
- Sponsor
- University College, London
Grief
Experiencing Loss and Planning Ahead Study
The course of dementia over many years, gradual losses and uncertain life expectancy can lead to grief amongst family and friend carers.
- Trial name
- ELPAS (NCT03332979)
- Where
- United Kingdom
- Volunteers
- 150 people
- Sponsor
- University College, London
Ulcer, Skin Ulcer
Epidermal Grafting in Wound Healing
Split thickness skin grafting is the normal standard of care for wound closure. However, this is an invasive procedure and associated with pain also there can be additional donor site morbidity.
- Conditions
- Ulcer, Skin Ulcer, Wounds and Injuries
- Trial name
- EPIGRAAFT (NCT02535481)
- Testing
- Epidermal grafting, Split thickness skin grafting
- Where
- United Kingdom
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University College, London